Voraxaze out-licensed in Japan
UK health care firm BTG (LSE: BGC) says that it has licensed the Japanese rights to glucarpidase (which carries the trade name Voraxaze) to Japan’s Ohara Pharmaceutical. Under the terms of the license agreement BTG will also supply glucarpidase to Ohara.
Ohara will be responsible for the development program and registration in Japan. The Japanese firm plans to work in partnership with leading oncologists who will execute clinical trials in a development program for glucarpidase. This is a clinical trial project funded by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor and Welfare (MHLW). An IND application for glucarpidase in Japan was submitted to the Pharmaceuticals and Medical Devices Agency on December 5. Should glucarpidase be successfully developed and approved, Ohara will have the rights to market and sell glucarpidase in Japan.
Ohara developing orphan drug business in Japan
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze